Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Erasca, Inc. and certain officers, alleging violations of federal securities laws. The suit covers investors who purchased or acquired Erasca securities between January 14, 2025 and April 26, 2026. The complaint claims defendants made false or misleading statements and failed to disclose that ERAS-0015’s preclinical data relied on improper comparisons to Revolution Medicines, Inc., exposing Erasca to patent and trade secret risks, and that they lacked a reasonable basis for positive statements about the drug candidate. Investors have until August 10, 2026 to seek lead plaintiff appointment. The law firm represents investors on a contingency fee basis.
Erasca IncClass action lawsuit alleging securities law violations and false statements about ERAS-0015.
Revolution Medicines Inc